Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of To Be Marketed Cholic Acid in Children with Inborn Errors of Bile Acid Synthesis
NCT01115582Phase 3Completed
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Start
- Apr 2010
- Primary completion
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cholic acid in inborn errors of bile acid synthesis, sponsored by Mirum Pharmaceuticals, Inc. Primary endpoints: Serum Transaminases at 30 days and Serum and Urine Bile Acids at 30 days. Started Apr 2010; status: completed.
02
Drugs
cholic acid
03
Conditions
inborn errors of bile acid synthesis
Beyond the preview
Go deeper on NCT01115582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01115582.